ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

Risk-Benefit Analysis Advised Prior To Hormone Therapy

August 27, 2010

FDA Rile Changes Reporting Requirements for Adverse Events

November 18, 1994

Panel Urges New Research Consortium For Stomach, Esophageal Cancers

January 17, 2003

Review Of Organ Site Program Requested By NCAB Set For Nov. 23-25; Eight Member Committee Named

August 21, 1981

MSK Investigators Report Sialic Acid Test 95% Accurate; Negative Immunotherapy Results Told

June 13, 1980

Stronger Measures Needed To Reduce Conflict of Interest, IOM Report Says

May 1, 2009